| Migraine With Brainstem Aura Drugs Market to Reach USD 1.51 Billion by 2031 | Growth Insights |
|
| Global Migraine With Brainstem
Aura drugs market is entering a phase of sustained expansion as healthcare
systems place greater emphasis on rare and complex neurological disorders.
Valued at USD 0.82 billion in 2024, the market is projected to gro |
| read more |
|
|
| Indian Manufacturers of Lactobacillus Reuteri: Driving the Future of Gut Health with Vakya Prob |
|
| In recent years, probiotics have become an essential part of preventive healthcare, and Lactobacillus Reuteri stands out as one of the most researched and clinically beneficial probiotic strains. Known for its ability to support digestive h |
| read more |
|
|
| Astaxanthin Market Size to Reach USD 352 Million by 2031 | Growth Trends & Insights |
|
| Global astaxanthin market is
gaining significant momentum as demand rises for natural antioxidants across
nutrition, cosmetics, and aquaculture applications. Valued at USD 182
million in 2024, the market is projected to reach USD 352 million by
2 |
| read more |
|
|
| Live Cell Imaging Market Size to Reach USD 2.83 Billion by 2031 | Growth Insights |
|
| Global live cell imaging market
is witnessing strong and sustained growth as real-time cellular analysis
becomes indispensable across drug discovery, biotechnology research, and
advanced diagnostics. Valued at USD 1.71 billion in 2024, the market |
| read more |
|
|
| Monoclonal Antibody Custom Service Market Size to Reach USD 1.63 Billion by 2032 |
|
| Global monoclonal antibody custom
service market is entering a phase of sustained expansion as biologics,
precision medicine, and translational research reshape modern drug development.
Valued at USD 1,055 million in 2024, the market is projected |
| read more |
|
|
| Sex Cord Gonadal Stromal Tumor Treatment Market to Reach USD 104 Million by 2031 |
|
| Global sex cord gonadal stromal
tumor (SCGST) treatment market is witnessing measured yet meaningful growth
as healthcare systems place increasing emphasis on rare cancer management,
personalized oncology, and surgical excellence. Valued at approx |
| read more |
|
|
